Last reviewed · How we verify
genteal gel
At a glance
| Generic name | genteal gel |
|---|---|
| Also known as | genteal |
| Sponsor | Lifelong Vision Foundation |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) (PHASE1, PHASE2)
- Effectiveness of Topical Magnetite Zinc Oxide Composite Nanoparticles in the Management of Oral Potentially Malignant Lesions (EARLY_PHASE1)
- A Study Comparing Different Treatment Approaches for the Initiation of Puberty in Girls With Turner Syndrome Using a TRIFECTA-DARED Approach for Rare Diseases (PHASE2)
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) (PHASE1, PHASE2)
- Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel (PHASE1)
- The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain (NA)
- Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period (PHASE4)
- The Effects of PeptiStrong and Exercise to Enhance Muscle Strength in Young Subjects (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- genteal gel CI brief — competitive landscape report
- genteal gel updates RSS · CI watch RSS
- Lifelong Vision Foundation portfolio CI